ADX40-A20 conjugate vaccine enhances tumor protection. (A) ADX40-A20 shows efficacy in the lymphoma tumor model, with significantly increased overall survival compared with the PBS, 20C2-A20, and KLH-A20 control groups (P < .0003). (B) Percentage of mice with tumors on day 15 after challenge showing a much lower percentage of ADX40-A20–immunized mice with tumors compared with the control groups. PBS, n = 39; 20C2-A20, n = 20; ADX40-A20, n = 50; and KLH-A20, n = 35.